drugset / Trial / NCT07365839
Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma
Phase 1
Not yet recruiting
20 enrolled
Virginia Commonwealth University
Regeneron Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized, 2-arm, non-comparative, pilot study assessing the efficacy of cemiplimab with or without fianlimab after treatment with yttrium-90 (Y90).
Timeline
- Start
- 2026-07-01
- Primary completion
- 2035-02-28
- Completion
- 2035-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Fianlimab | Monoclonal antibody | 1600 mg | Intravenous |